Form FDA 483 · Issued 2026-02-27
Reliance Life Sciences Private Limited — FDA Form 483 Analysis
FEI: 3009510975 · Sector: Pharmaceuticals & Sterile/OTC Drugs (Drug Manufacturer) · Lead Investigator: Marcus V. Delgado
FDA Form 483 issued to Reliance Life Sciences Private Limited (FEI 3009510975) on 2026-02-27 following an inspection of its drug manufacturer operations in India. The report documents 2 inspection observations centered on Finished Product Testing, Stability & Expiration Dating.
Get Full Annotated 483 Dossier + CAPA Checklist
Instant PDF + CFR Matrix ($79 vs. Redica's $289)
Need Help Fixing These 2 Citations?
Get matched with a vetted 21 CFR remediation consultant
Observation-by-Observation 21 CFR Breakdown (2)
Observation #1 · 21 CFR 211.186(b)(9)
Finished Product Testing, Stability & Expiration Dating
REPEAT CITATION AT FACILITY
Manufacturing Instructions and Specifications
Inspector Observation Language: "The master production and control records are deficient in that they do not include complete [manufacturing and control instructions] [sampling procedures] [testing procedures] [specifications] [special notations] [precautions to be followed]. Specifically, observed during inspection of Reliance Life Sciences Private Limited on 2026-02-27."
Plain-English Meaning: Releasing finished batches without verifying strength/potency/microbiological specs, or placing an expiration/best-by date on labels without supporting real-time or accelerated stability data.
Standard CAPA Remediation Path: Require finished-batch microbiological (USP <2021>/<2022>), heavy metal, and active-assay release testing plus ICH stability chamber protocols supporting every label shelf-life claim.
Observation #2 · 21 CFR 211.186(b)(9)
Finished Product Testing, Stability & Expiration Dating
FIRST-TIME OBSERVATION
Complete instructions, procedures, specifications et. al.
Inspector Observation Language: "Master production and control records lack [complete manufacturing and control instructions] [sampling and testing procedures] [specifications] [special notations] [precautions to be followed]. Specifically, observed during inspection of Reliance Life Sciences Private Limited on 2026-02-27."
Plain-English Meaning: Releasing finished batches without verifying strength/potency/microbiological specs, or placing an expiration/best-by date on labels without supporting real-time or accelerated stability data.
Standard CAPA Remediation Path: Require finished-batch microbiological (USP <2021>/<2022>), heavy metal, and active-assay release testing plus ICH stability chamber protocols supporting every label shelf-life claim.